Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma-Reference-Cited by-同舟云学术

Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma

Published:2017-06-08 Issue:6 Volume:12 Page:e0179000
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wang Lin,Tang Chuanhao,Xu Bin,Yang Lin,Qu Lili,Li Liangliang,Li Xiaoyan,Wang Weixia,Qin Haifeng,Gao Hongjun,He Kun,Liu Xiaoqing^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference34 articles.

1. Cancer statistics, 2016;RL Siegel;Ca A Cancer Journal for Clinicians,2016

2. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J];D S Ettinger;Journal of the National Comprehensive Cancer Network Jnccn,2017

3. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes;P Tomasini;Therapeutic Advances in Medical Oncology,2016

4. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;GV Scagliotti;J Clin Oncol,2008

5. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis;H-Q Xiao;OncoTargets and therapy,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining serum peptide signatures with International Federation of Gynecology and Obstetrics (FIGO) risk score to predict the outcomes of patients with gestational trophoblastic neoplasia (GTN) after first-line chemotherapy;Frontiers in Oncology;2022-10-21

2. Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification;Translational Lung Cancer Research;2021-02

3. Hypertensive disorders of pregnancy: Strategy to develop clinical peptide biomarkers for more accurate evaluation of the pathophysiological status of this syndrome;Advances in Clinical Chemistry;2020

4. The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer “Omics”;International Journal of Molecular Sciences;2019-05-25

5. Probing the endogenous peptidomes of cancer for biomarkers: A new endeavor;Advances in Clinical Chemistry;2019